Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 6
Journal homepage
3
Views
3
CrossRef citations to date
0
Altmetric
Anti-Inflammatory, Anti-Allergic, Respiratory & GI Agents

Overview: Recent Developments in Sulphidopeptide Leukotriene Receptor Antagonists

Robert A Galemmo Jr Rhône-Poulenc Rorer Central Research, Collegeville, PA 19426, USA
,
Ashvin Gavai Rhône-Poulenc Rorer Central Research, Collegeville, PA 19426, USA
&
Fu-Chih Huang Rhône-Poulenc Rorer Central Research, Collegeville, PA 19426, USA
Pages 811-833 | Published online: 02 Mar 2011

References to Primary Literature

  • Bjork T, Harada Y, Dahlen B, Zetterstrom O, Johansson G, Rodriguez L, Helqvist P, Dahlen S-E Further evidence that leukotrienes are the major mediators of allergic constriction in human bronchi. Adv. Prostaglandin Thromoboxane Leukotriene Res. 1990 21 429–432.
  • Shaw A, Krell RD Peptide Leukotrienes: Current Status of Research. J. Med. Chem. 1991 34 1235–1242.
  • Niel G, Escale R, Vidal JP, Rechencq E, Girard JP, Rossi JC Synthesis of a new pseudopeptidoleukotriene: The first LTD4 analogue with potent agonist activity. Tetrahedron Lett. 1991 32 2613–2614.
  • Lewis RA, Austen KF, Drazen JM, Soter NA, Gifueirdo JC, Corey EJ Structure, function and metabolism of leukotriene constituents of SRS-A. Leukotrienes and Other Lipoxygenase Products Samulesson B Paoletti R Raven Press New York 1982, 137–151.
  • Lewis RA, Lee CW, Levine L, Morgan RA, Weiss JW, Drazen JM, Oh H, Corey EJ, Austin KF Biology of the C-6 sulfidopeptide leukotrienes. Adv. Prostaglandin Thromoboxane Leukotriene Research Samulesson B Paoletti R Ramwell P Raven Press New York 1983 11 15–26.
  • Gleason JG, Hall RF, Perchonock CD, Erhard KF, Frazee JS, Ku TW, Kondard K, McCarthy ME, Mong S, Crooke ST, Chi-Rosso G, Wasserman MA, Torphy TJ, Muccitelli RM, Hay DW, Tucker SS, Vickery-Clark L High affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl]propanoic acid. J. Med. Chem. 1987 30 959–961.
  • Hay DWP, Newton JF, Torphy TJ, Gleason JG SK&F 104,353. Drugs Future 1990 15 240–244.
  • Smith EF III, Slivjak MJ, Eckardt RD, Newton JF Antagonism of leukotriene C4 leukotriene D4 and leukotriene E4 vasoconstrictor responses in the conscious rat with the peptidoleukotriene receptor antagonist SK&F 104,353: Evidence for leukotriene D4 receptor heterogeneity. J. Pharm. Exp. Ther. 1989 249 805–811.
  • Pharma projects May, 1991 PJB Publications Ltd., Richmond, Surrey, UK.
  • Boot JR, Bond A, Gooderham R, O'Brien A, Parsons M, Thomas KH The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea pig. Br. J. Pharmacol. 1989 98 259–267.
  • Baker SR, Boot JR, Lucas R, Wishart G Sulukast. Drugs Future 1991 16 432–436.
  • Sabol JS, Cregge RJ Conformationally restricted leukotriene antagonists. Asymmetric synthesis of some nor-leukotriene D4 analogs. Tetrahedron Lett. 1989 30 3377–3380.
  • Sabol JS, Cregge RJ Conformationally restricted leukotriene antagonists. Synthesis of some leukotriene D4 analogs from D-xylose. Tetrahedron Lett. 1989 30 6271–6274.
  • Sabol JS, Cregge RJ Conformationally restricted leukotriene antagonists. Asymmetric synthesis of a nor-leukotriene D4 analog. Il. Tetrahedron Lett. 1990 31 27–30.
  • Sabol JS, Weintraub PM, Gieske TH, Cregge RJ Conformationally restricted leukotriene antagonists. Stereoselective synthesis of some leukotriene D4 analogs. Tetrahedron 1990 46 4155–4160.
  • Cregge RJ, Lentz NL, Sabol JS Conformationally restricted leukotriene analogs. Synthesis of chiral 4-hydroxy-4-alkylcyclohexanecarboxylic acids as leukotriene analogs. J. Org. Chem. 1991 56 1758–1763.
  • Krell RD, Aharony D, Buckner CK, Kusner EJ Peptide leukotriene receptors and antagonists. Adv. Prostaglandin Thromboxane Leukotriene Res. 1990 20 119–126 This review outlines the current thinking on the heterogeneity of the leukotriene receptor and proposes a system of classification of the various subtypes.
  • Gieske TH, Sabol JS, Weintraub PM, Raddatz R, Cregge RJ Conformationally restricted leukotriene D4 receptor antagonists: ((octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio) acetic acids. Pharmacology 1990 40 271–276.
  • Gieske TH, Sabol JS, Raddatz R MDL 28753 an agonist of LTD4 but an antagonist of LTC4 in longitudinal muscle in guinea pig. J. Pharmacol. Exp. Ther. 1990 254 192–197.
  • Nakai H, Konno M, Kosuge S, Sakuyama S, Toda M, Arai Y, Obata T, Katsube N, Miyamoto T, Okegawa T, Kawasaki A New potent analogs of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships. J. Med. Chem. 1988 31 84–91.
  • Akira I, Nakagawa T, Motoishi M, Miyamoto T Inhibition of endogenous leukotrienemediated lung anaphylaxis in guinea pigs by a novel receptor antagonist ONO 1078. Int. Arch. Allergy Appl. Immunol. 1990 92 404–407.
  • Nakagawa T, Mizushima Y, Ishii A, Nambu F, Motoishi M, Yui Y, Shida T, Miyamoto T Effect of a leukotriene antagonist on experimental and clinical asthma. Adv. Prostaglandin Thromboxane Leukotriene Res. 1990 21 465–468.
  • Augustein J, Farmer JB, Lee TB, Sheard P, Tattersall ML Selective inhibitor of slow reacting substance of anaphylaxis. Nature (London) New Biol. 1973 245 215–217 The report describes the first selective LTD4/LTE4 antagonist identified.
  • Appleton RA, Bantick JR, Chamberlain TR, Hardern DN, Lee TB, Pratt AD Antagonists of slow reacting substance of anaphylaxis. Synthesis of a series of chromone-2-carboxylic acids. J. Med. Chem. 1977 20 371–379.
  • Marshall WS, Whitesitt CA, Goodson T, Roman C, Rinkema L, Fleisch JH Structure-activity relationships of the 3-alkyl substituents among a series of hydroxy acetophenone leukotriene antagonists. Agents Actions 1987 21 275–277.
  • Brown FJ, Bernstein PR, Cronk LA, Dosset DL, Hebbel KC, Maduskuie TP, Shapiro HS, Vacek EP, Yee YK, Willard AK, Krell RD, Snyder DW Hydroxyacetophenone derived antagonists of the peptidoleukotrienes. J. Med. Chem. 1989 32 807–826.
  • Dillard RD, Carr FP, McCullough, Haisch KD, Rinkema LE, Fleisch JH Leukotriene receptor antagonists. 2. The [[(tetrazol-5-yl)oxy]methyl]acetophenone derivatives. J. Med. Chem. 1987 30 911–918.
  • Marshall WS, Goodson T, Cullinan GJ, Swanson-Bean D, Haisch KD, Rinkema LE, Fleisch JH Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives. J. Med. Chem. 1987 30 682–689.
  • Fleisch JH, Rinkema LE, Haisch KD, Swanson-Bean D, Goodson T, Ho PPK, Marshall WS LY 171883, 1-[2-hydroxy-3-propyl-4-[4-(1H-tetrazol-5-yl)butoxy]phenyl]ethanone, an orally active leukotriene D4 antagonist. J. Pharmacol. Exp. Ther. 1985 233 148–157.
  • Phillips GD, Rafferty P, Robinson C, Holgate ST Dose-related antagonism of leukotriene induced bronchoconstriction by po administration of LY 171883 in nonasthmatic subjects. J. Pharmacol. Exp. Ther. 1988 246 732–738.
  • Fuller RW, Black PN, Dollery CT Effect of the oral leukotriene D4 antagonist LY171–883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects. J. Allergy Clin. Immunol. 1989 83 939–944.
  • Israel E, Juniper EF, Callaghan JT, Mathur PN, Morris MM, Dowell AR, Enas GG, Hargreave FE, Drazen JM Effect of a leukotriene antagonist, LY 171883, on cold air-induced bronchoconstriction in asthmatics. Am. Rev. Respir. Dis. 1989 140 1348–1353.
  • Cloud ML, Enas GG, Kemp J, Platts-Mills T, Altman LC, Townley R, Tinkelman D, King T, Middleton E, Sheffer AL, McFadden ER, Farlow DS A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am. Rev. Respir. Dis. 1989 140 1336–1339.
  • Rinkema LE, Roman CR, Russell WL, Spaethe SM, Bemis KG, Henry DP, Marshall WS, Fleisch JH Leukotriene receptor antagonism and augmentation of β-receptor mediated events by LY 171883. J. Pharm. Pharmacol. 1990 42 620–625.
  • Hoover DM, Bendele AM, Hoffman WP, Foxworthy PS, Eacho PI Effects of chronic treatment with the leukotriene D4 antagonist compound LY 171883 on Fischer 344 rats and Rhesus monkeys. Funda. Appl. Toxicol. 1990 14 123–130.
  • Bendele AM, Hoover DM, Van Leer RBL, Foxworthy PS, Eacho PI Effects of chronic treatment with the leukotriene antagonist compound LY 171883 on B6C3F1 mice. Funda. Appl. Toxicol. 1990 15 676–682.
  • Fleisch JH, Rinkema LE, Haisch KD, McCullough D, Carr FP, Dillard RD Evaluation of LY 163443, 1-[2-hydroxy-3-propyl-4-[4-(1 H-tetrazol-5-yl)phenoxymethylphenyl ethanone, as a pharmacological antagonist of leukotrienes D4 and E4. N.S. Arch. Pharmacol. 1986 333 70–77.
  • Marshall WS, Sigmund SK, Whitesitt CA, Lifer SL, Roman CR, Rinkema LE, Hahn RA, Fleisch JH Leukotriene receptor antagonists. Heterocycle-linked tetrazoles and carboxylic acids. LY 203647. Agents Actions 1989 27 309–312.
  • Dillard RD, Hahn RA, McCullough D, Carr FP, Rinkema LE, Roman CR, Fleisch JR (Phenylmethoxy)phenyl derivatives of Ω-oxo- and Ωtetrazolylalkanoic acids and related tetrazoles. Synthesis and evaluation as leukotriene D4 receptor antagonists. J. Med Chem. 1991 34 2768–2778.
  • Jones TR, Young R, Champion E, Charette L, Denis D, Ford-Hutchinson AW, Frenette R, Gauthier J-Y, Guidon Y, Kakushima M, Masson P, McFarlane C, Piechuta H, Rokach R, Zamboni R L 649923, sodium (βS*,γR*)4-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)propylthio)-γ-hydroxy β-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonist. Can. J. Physiol. Pharmacol. 1986 64 1068–1075.
  • Young RN, Belanger P, Champion E, DeHaven RN, Denis D, Ford-Hutchinson AW, Forttn R, Frenette R, Gauthier JY, Gillard J, Guindon Y, Jones TR, Kakushima M, Masson P, Maycock A, McFarlane CS, Piechuta H, Pong SS, Rokach J, Williams HWR, Yoakim C, Zamboni R Design and synthesis of sodium (βR*,γS*)-4[[3-(-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-γ-hydroxy-β-methylbenzenebutanoate: A novel, selective and orally active receptor antagonist of leukotriene D4. J. Med. Chem. 1986 29 1573–1576.
  • Jones TR, Guindon Y, Young R, Champion E, Charette L, Denis D, Ethier D, Hame R, Ford-Hutchinson AW, Fortin R, Letts G, Masson P, McFarlane C, Piechuta H, Rokach J, Yoakim C L 648051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl]-γ-oxobenzen-ebutanoate: A leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 1986 64 1535–1542.
  • Young RN L 648051, a potent and specific aerosol active leukotriene D4 anatgonist. Agents Actions Suppl. 1988 23 113.
  • Britton JR, Hanley SP, Tattersfield AE The effect of an oral leukotriene D4 antagonist L 649923 on the response to inhaled antigen in asthma. J. Allergy Clin. Immunol. 1987 79 811–816.
  • Barnes N, Piper PJ, Costello J The effect of an oral leukotriene antagonist L 649923 on histamine and leukotriene D4 induced bronchoconstriction in normal man. J. Allergy Clin. Immunol. 1987 79 816–821.
  • Siren A-L, Eimerl J, Feuerstein G L 649923: An antagonist of cardiac and vascular leukotriene D4 receptors. J. Cardiovascular Pharmacol. 1989 13 210–217.
  • Sanders JE, Eigenberg DA, Bracht LJ, Wang WR, Van Zwieten MJ Thyroid and liver trophic changes in rats secondary to liver microsomal enzyme induction caused by experimental leukotriene antagonist (L 649923). Toxicol. Appl. Pharmacol. 1988 95 378–387.
  • Evans JM, Barnes NC, Zakrzewski JT, Sciberras DG, Stahl EG, Piper PJ, Costello JF L 648051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man. Br. J. Clin. Pharmacol. 1989 28 125–135.
  • Von Sprecher A, Beck A, Sallmann A, Breitenstein W, Wiestner H, Brokatzky-Geiger J, Eisler K, Gamboni R, Rosslein L, Schlinghoff G, Nissim CC, Bach L-H, Anderson GP, Subramanian N, Bray M CGP 45715A, a potent peptidoleukotriene antagonist based on the structure of LTD4. Med. Chem. Res. 1991 1 195–200.
  • Von Sprecher A, Beck A, Sallmann A, Breitenstein W, Wiestner H, Kimmel S, Anderson GP, Subramanian N, Bray M Peptidoleukotriene antagonists: Structural analogs of leukotriene D4 with special emphasis on CGP45715A. Drugs Future 1991 16 827–843 This review is an excellent discussion of the design considerations involved in the optimization of LTD4/LTE4 antagonist activity.
  • Tomioka K, Yamada T, Mase T, Hara H, Murase K Pharmacological properties of the orally active leukotriene antagonist [[5-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetic acid. Arzneim. Forsch. 1988 38 682–685.
  • Tomioka K, Garrido R, Stevenson JS, Abraham WM The effect of an orally active leukotriene (LT) antagonist YM-16638 on antigen-induced early and late airway responses in allergic sheep. Prost. Leuk. Essen. Fatty Acids 1989 36 43–47.
  • Cohen N, Weber G, Banner BL, Lopresti RJ, Schaer B, Focella A, Zenchoff GB, Chiu A-M, Todaro L, O'Donnell M, Welton AF, Brown D, Garippa R, Crowley H, Morgan DW 3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists. J. Med. Chem. 32 1842–1860.
  • Carnathan GW, Sanner JH, Thompson JM, Prusa CM, Miyano M Antagonism of the in vivo and in vitro effects of leukotriene D4 by SC-39070 in guinea pigs. Agents Actions 1987 20 124–132.
  • Huang F-C (2-Quinolinylmethoxy)phenyl-containing compounds as leukotriene receptor antagonists: A brief review of structure activity relationships and the biological profile of RG 12525. Drugs Future 1991 16 1121–1127 This review is a comprehensive discussion of the structure-activity relationships for this important class of leukotriene antagonists.
  • Musser JH, Chakraborty UR, Sciortino S, Gordon RJ, Khandwala A, Neiss ES, Pruss TP, Van Inwegen R, Weinryb I, Coutts SM Substituted arylmethyl phenyl ethers. 1. A novel series of 5-lipoxygenase inhibitors and leukotriene antagonists. J. Med. Chem. 1987 30 96–104.
  • Youssefyeh RD, Magnien E, Lee TDY, Chan W-K, Lin CJ, Galemmo RA Jr., Johnson WH Jr., Tan J, Campbell HF, Huang F-C, Nuss GW, Carnathan GW, Sutherland CA, Van Inwegen RG Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships. J. Med. Chem. 1990 33 1186–1194.
  • Galemmo RA Jr., Johnson WH Jr., Learn KS, Lee TDY, Huang F-C, Campbell HF, Youssefyeh R, O'Rourke SV, Schuessler G, Sweeney DM, Travis JJ, Sutherland CA, Nuss GW, Carnathan GW, Van Inwegen RG The development of a novel series of (quinolin-2-ylmethoxy)phenyl containing compounds as high-affinity leukotriene receptor antagonists. 3. Structural variation of the acidic side chain to give antagonists of enhanced potency. J. Med. Chem. 1990 33 2828–2841.
  • Huang F-C, Galemmo RA Jr., Johnson WH Jr., Poli GB, Morrissette MM, Mencel JJ, Warus JD, Campbell HF, Nuss GW, Carnathan GW, Van Inwegen RG Development of a novel series of (2-quinolinylmethoxy)phenyl containing compounds as high-affinity leukotriene receptor antagonists. 2. Effects of an additional phenyl ring on receptor affinity. J. Med. Chem. 1990 33 1194–1200.
  • Wahedna I, Wisniewski AS, Tattersfield AE Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma. Brit. J. Clin. Pharm. 1991 32 512–515.
  • Huang F-C, Galemmo RA Jr., Poli GB, Learn KS, Morrissette MM, Johnson WH Jr, Dankulich WP, Campbell HF, Carnathan GW, Van Inwegen RG Development of a novel series of (2-quinolinylmethoxy)phenyl containing compounds as high affinity leukotriene receptor antagonists. 4. Addition of chromone moiety enhances leukotriene D4 receptor binding affinity. J. Med. Chem. 1991 34 1704–1707.
  • Musser JH, Kreft AF, Bender RHW, Kubrak DM, Carlson RP, Chang J, Hand JM N-[(Arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: Potent orally active leukotriene D4 antagonists of novel structure. J. Med. Chem. 1989 32 1176–1183.
  • Musser JH, Kreft AF, Bender RHW, Kubrak DM, Grimes D, Carlson RP, Hand JM, Chang J N-[(Arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure. J. Med. Chem. 1990 33 240–245.
  • Musser JH, Kreft AF Substituted-[2-quinilinyl(bridged)aryl] compounds: Modulators of eicosanoid biosynthesis and action. Drugs Future 1990 15 73–80.
  • Shaw A, Krell RD Peptide leukotrienes: Current status of research. J. Med. Chem. 1991 34 1235–1242.
  • Hand JM, Auen MA, Chang J, Englebach IM Prevention and reversal of aerosol LTD4-induced changes in guinea pig pulmonary mechanics by Wy-48252, an orally active LTD4/E4 receptor antagonist. Int. Arch. Allergy Appl. Immunol. 1989 89 78–82.
  • Ahnfelt-Ronne I, Kirstein D, Kaergaard-Nielsen C A novel leukotriene D4/E4 antagonist, SR 2640 (2-[3-(2-quinolinylmethoxy) phenylamino]benzoic acid). Eur. J. Pharmacol. 1988 155 117–128.
  • Christensen A, Kissmeyer A-M, Eilertsen E, Rastrup-Andersen N, Ronne Ahnfelt I Pharmacokinetics and metabolism of a leukotriene antagonist (2-[3′-(2″-quinolylmethoxy)phenylamino]benzoic acid) in rat, dog, guinea pig and man. Xenobiotica 1990 20 417–434.
  • Thomsen MK, Ahnfelt-Ronne I Inhibition by LTD4 antagonist, SR 2640, of effects of LTD4 on canine polymorphonuclear leukocyte functions. Biochem. Pharmacol. 1989 38 2291–2295.
  • Bouchelouche PN, Ahnfelt-Ronne I, Thomsen MK LTD4 increases cytosolic free calcium and inositol phosphate in human neutrophils: Inhibition by the novel LTD4 receptor antagonist, SR 2640, and possible relation to the modulation of chemotaxis. Agents Actions 1990 29 299–307.
  • Nielsen OH, Ahnfelt-Ronne I, Thomsen MK, Kissmeyer A-M, Langholz E Effect of the leukotriene D4/E4 antagonist, SR 2640, in ulcerative colitis: An open clinical study. Prostaglandins Leukotrienes Essen. Fatty Acids 1991 42 181–184.
  • Young RN Structural analysis of sulfidopeptide leukotrienes: Application to the design of potent and specific antagonists of leukotriene. Adv. Prostaglandin Thromboxane Leukotriene Res. 1989 19 643–646 This paper discusses the currently accepted model for the sulphidopeptide leukotriene receptor.
  • Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Frenette R, Gauthier J-Y, Leger S, Masson P, McFarlane CS, Piechuta H, Rokach J, Williams H, Young RN Pharmacology of L 660711 (MK 571): A novel potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 1989 67 17–28.
  • Gauthier JY, Jones T, Champion E, Charette L, Dehaven R, Ford-Hutchinson AW, Hoogsteen K, Lord A, Masson P, Piechuta H, Pong SS, Springer JP, Therien M, Zamboni R, Young RN Stereospecific synthesis, assigment of absolute configuration, and biological activity of enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl][3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid. J. Med. Chem. 1990 33 2841–2845.
  • Denzlinger C, Grimberg M, Kapp A, Haberl C, Wilmanns W Effect of the leukotriene receptor antagonists FPL 55712, LY 16443 and MK 571 on the elimination of cysteinyl leukotrienes in the rat. Br. J. Pharmacol. 1991 102 865–870.
  • Kips J, Joos GF, De Lepeleire I, Margolskee DJ, Buntinx A, Pauwels RA, Van Der Straeten ME MK 571, a potent antagonist of leukotriene D4 induced bronchoconstriction in the human. Am. Rev. Respir. Dis. 1991 144 617–621.
  • Ford-Hutchinson AW Regulation of the production and action of leukotrienes by MK 571 and MK 886. Adv. Prostaglandin Thromboxane Leukotriene Res. 1990 21 9–16.
  • Hendeles L, Davison D, Blake K, Harman E, Cooper R, Margolskee D Leukotriene D4 is an important mediator of antigen induced bronchoconstriction: Attenuation of the dual response with MK 571, a specific LTD4 receptor antagonist. J. Allergy Clin. Immunol. 1990 85 197A.
  • Gaddy J, Bush RK, Margolskee D, Williams VC, Busse W The effects of leukotriene D4 antagonist MK 571 in mild to moderate asthma. J. Allergy Clin. Immunol. 1990 85 197A.
  • Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JL, O'Byrne PM Inhibition of exercise induced bronchoconstriction by MK 571, a potent leukotriene receptor antagonist. N. Engl. J. Med. 1990 323 1736–1739.
  • Bernstein PR, Snyder DW, Adams EJ, Krell RD, Vacek EP, Willard AK Chemically stable homocinnamyl analogs of the leukotrienes: Synthesis and preliminary biological evaluation. J. Med. Chem. 1986 29 2477–2483.
  • Bernstein PR, Vacek EP, Adams EJ, Snyder DW, Krell RD Synthesis and pharmacological characterization of a series of leukotriene analogs with antagonist and agonist activities. J. Med. Chem. 1988 31 692–696.
  • Snyder DW, Bernstein PR U19052 (ICIAm): A novel leukotriene analog which antagonizes LTC4, LTD4 and LTE4. Prostaglandins 1988 35 903–914.
  • Yee YK, Brown FJ, Hebbel KC, Cronk LA, Snyder DW, Krell RD Structure-activity relationships based on the peptide leukotriene receptor antagonist ICI 198615. Ann. N.Y. Acad. Sci. 1988 524 458–461.
  • Brown FJ, Yee YK, Cronk LA, Hebbel KC, Krell RD, Snyder DW Evolution of a series of peptidoleukotriene antagonists: Synthesis and structure-activity relationships of 1,6 disubstituted indoles and indazoles. J. Med. Chem. 1990 33 1771–1781.
  • Matassa VG, Maduskuie TP, Shapiro HS, Hesp B, Snyder DW, Aharony D, Krell RD, Keith RA Evolution of a series of peptidoleukotriene antagonists: Synthesis and structure-activity relationships of 1,3,5 substituted indoles and indazoles. J. Med. Chem. 1990 33 1781–1790.
  • Yee YK, Bernstein PR, Adams EJ, Brown FJ, Cronk LA, Hebbel KC, Vacek EP, Krell RD, Snyder DW A novel series of selective leukotriene antagonists: Exploration and optimization of the acidic region in 1,6 disubstituted indoles and indazoles. J. Med. Chem. 1990 33 2437–2451.
  • Matassa VG, Brown FJ, Bernstein PR, Shapiro HS, Maduskuie TP, Cronk LA, Vacek EP, Yee YK, Snyder DW, Krell RD, Lerman CL, Maloney JJ Synthesis and in vitro LTD4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides. J. Med. Chem. 1990 33 2621–2629.
  • Snyder DW, Giles RE, Keith RA, Yee YK, Krell RD In vitro pharmacology of ICI 198615: A novel, potent and selective peptide leukotriene antagonist. J. Pharm. Exp. Ther. 1987 243 548–556.
  • Aharony D, Catanese CA, Falcone RC Kinetic and pharmacologic analysis of [3H] leukotriene E4 binding to receptors on guinea pig lung membranes: Evidence for selective binding to a subset of leukotriene D4 receptors. J. Pharm. Exp. Ther. 1988 248 581–588.
  • Shirley JT, Cheng JB Competition of leukotrienes and ICI 198615 for [3H]LTD4 binding sites in guinea pig lung membrane suggests the involvement of two LTD4 receptor subtypes. J. Pharm. Exp. Ther. 1991 258 531–536.
  • Smith EF, Slivjak MJ ICI 198615 is an antagonist of leukotriene C4, leukotriene D4, and leukotriene E4 vasopressor responses in the conscious rat. Pharmacology 1990 41 57–66.
  • Krell RD, Kusner EJ, Aharony D, Giles RE Biochemical and pharmacological characterization of ICI 198615: A peptide leukotriene receptor antagonist. Eur. J. Pharmacol. 1989 159 73–81.
  • Falcone RC, Orzechowski RF, Aharony D Specific binding of 3H-ICI 198615, a potent LTD4 antagonist, to guinea pig cardiac ventricular membranes. Prostaglandins 1990 39 241–258.
  • Krell RD, Giles RE, Yee YK, Snyder DW In vivo pharmacology of ICI 198615: A novel, potent and selective peptide leukotriene antagonist. J. Pharm. Exp. Ther. 1987 243 557–564.
  • Krell RD, Aharony D, Buckner CK, Keith RA, Kusner EJ, Snyder DW, Bernstein PR, Matassa VG, Yee YK, Brown FJ, Hesp B, Giles RE The preclinical pharmacology of ICI 204219. Am. Rev. Respir. Dis. 1990 141 978–987.
  • Smith LJ, Geller S, Ebright L, Glass M, Thyrum PT Inhibition of LTD4 induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204219. Am. Rev. Respir. Dis. 1990 141 988–992.
  • Bernstein JA, Greenberger PA, Patterson R, Glass M, Krell R, Thyrum PT The effect of the oral leukotriene antagonist, ICI 204219, on leukotriene D4 and histamine induced cutaneous vascular reactions in man. J. Allergy Clin. Immunol. 1991 87 93–98.
  • O'Donnell M, Crowley HJ, Yaremko B, O'Neill N, Welton AF Pharmacologic actions of Ro 24–5913, a novel antagonist of leukotriene D4. J. Pharm. Exp. Ther. 1991 259 751–758.
  • Gillad JW, Guidon Y The leukotrienes: Prospects for therapy against a unique family of pathophysiological mediators. Drugs Future 1987 12 453–474.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.